May 26, 2022
CASI Pharmaceuticals Announces Reverse Stock SplitMay 24, 2022
CASI Pharmaceuticals Enters Into Sublicense Agreement With Tianshi Pharmaceuticals For Anti-CD38 Monoclonal Antibody (MAB) CID-103 In Autoimmune FieldMay 12, 2022
CASI Pharmaceuticals Announces First Quarter 2022 Financial ResultsMay 02, 2022
CASI Pharmaceuticals to report first quarter 2022 financial results and host conference call May 12, 2022April 01, 2022
CASI Pharmaceuticals Statement On Status Under Holding Foreign Companies Accountable ActMarch 28, 2022
CASI Pharmaceuticals Announces Full-Year 2021 Financial Results And Fourth Quarter 2021 Evomela® RevenueMarch 23, 2022
CASI Pharmaceuticals To Report Fourth Quarter And Year End 2021 Financial Results And Host Conference Call March 28, 2022March 04, 2022
CASI Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In ChinaFebruary 16, 2022
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2021 Revenues And Provides Business UpdatesJanuary 20, 2022
CASI Pharmaceuticals Partner, BioInvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA For The Treatment Of Patients With Follicular LymphomaJanuary 18, 2022
CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Granted Orphan Drug Designation By The U.S. FDAJanuary 03, 2022
CASI Pharmaceuticals Receives Nasdaq Deficiency NoticeDecember 17, 2021
CASI Pharmaceuticals Announces Stock Repurchase ProgramDecember 10, 2021
CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In ChinaNovember 15, 2021
CASI Pharmaceuticals To Present At Jefferies London Healthcare ConferenceNovember 12, 2021
CASI Pharmaceuticals Announces Third Quarter 2021 Financial ResultsNovember 05, 2021
CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021November 02, 2021
CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021October 25, 2021
CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And CommercializationSeptember 20, 2021
CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
